Loading clinical trials...
Loading clinical trials...
A multicenter phase 3 safety trial in which 5,700 subjects will be assigned in a 2:1 ratio to receive 120 μg rLP2086 vaccine in a 0, 2, 6 month schedule or control. The control group will receive HAVR...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Pfizer
NCT05252715 · Meningitis, Meningococcal
NCT03549325 · Meningitis, Meningococcal
NCT03295318 · Meningitis, Meningococcal
NCT03493919 · Meningitis, Meningococcal
NCT03205371 · Meningitis, Meningococcal
Accelovance,Inc.
Huntsville, Alabama
Clinical Research Advantage, Inc. / East Valley Family Physicians, PLC
Chandler, Arizona
Clinical Research Advantage, Inc/ East Valley Family Physicians, PLC
Chandler, Arizona
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions